1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B
virus infection: new estimates of age-specific HBsAg seroprevalence and
endemicity. Vaccine. Elsevier Ltd. 2012;30(12):2212–9.
2. Rey J, Stanaway D, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, et al. The
global burden of viral hepatitis from 1990 to 2013: findings from the global
burden of disease study 2013. Lancet. 2016;6736(16):1–8.
3. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of
worldwide prevalence of chronic hepatitis B virus infection: a systematic
review of data published between 1965 and 2013. Lancet. Elsevier Ltd.
2015;6736(15):1–10.
4. WHO. Hepatitis B fact sheet updated: World Health Organization; 2017.
Available from: http://www.who.int/mediacentre/factsheets/fs204/en/.
Accessed 11 Aug 2017.
5. Forouzanfar MH, Afshin A, Alexander LT, Biryukov S, Brauer M, Cercy K, et al.
Global, regional, and national comparative risk assessment of 79
behavioural, environmental and occupational, and metabolic risks or
clusters of risks, 1990–2015: a systematic analysis for the global burden of
disease study 2015. Lancet. 2016;388:1659–724.
6. Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global
burden of cancers attributable to infections in 2012: a synthetic analysis.
Lancet Glob Heal The Author(s). Published by Elsevier Ltd. This is an Open
Access article under the CC BY-NC-ND license. 2016;4(9):e609–16.
7. Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L. Hepatitis B:
epidemiology and prevention in developing countries. World J Hepatol.
2012;4(3):74–80.
8. Kramvis A, Kew MC. Epidemiology of hepatitis B virus in Africa, its
genotypes and clinical associations of genotypes. Hepatol Res. 2007;
37(SUPPL. 1):9–19.
9. Nelson NP, Jamieson DJ, Murphy TV. Prevention of perinatal hepatitis B virus
transmission. J Pediatric Infect Dis Soc. 2014;3(suppl 1):7–12.
Page 10 of 11
10. Li Z, Hou X, Cao G. Is mother-to-infant transmission the most important
factor for persistent HBV infection? Emerg Microbes Infect. 2015;4(5):e30.
11. McMahon BJ, Alward WLM, Hall DB. Acute hepatitis B virus infection:
relation of age to the clinical expression of disease and subsequent
development of the carrier state. J Infect Dis. 1985;151(4):599.
12. WHO. Global health sector strategy on viral hepatitis 2016–2021: WHO Press;
2016. Available from: http://www.who.int/hepatitis/strategy2016-202.
Accessed 8 Aug 2017.
13. WHO. Global Health estimates 2015: deaths by cause, age, sex, by country
and by Region, 2000–2015; 2016. Available from: http://www.who.int/
healthinfo/global_burden_disease/estimates/en/index1.html. Accessed 11
Aug 2017.
14. Nannini P, Sokal EM. Hepatitis B: changing epidemiology and interventions.
Arch Dis Child. 2016; https://doi.org/10.1136/archdischild-2016-312043.
15. Nagalo MB, Sanou M, Bisseye C, Kaboré MI, Nebie YK, Kienou K, et al.
Seroprevalence of human immunodeficiency virus, hepatitis B and C viruses
and syphilis among blood donors in Koudougou (Burkina Faso) in 2009.
Blood Transfus. 2011;9(4):419–24.
16. Tao I, Compaoré TR, Diarra B, Djigma F, Zohoncon TM, Assih M, et al.
Seroepidemiology of hepatitis B and C viruses in the general population of
Burkina Faso. Hepat Res Treat. 2014;2014:1–5.
17. Sangaré L, Sombié R, Combasséré AW, Kouanda A, Kania D, Zerbo O, et al.
Antenatal transmission of hepatitis B virus in an area of HIV moderate
prevalence, Burkina Faso. Bull Soc Pathol Exot. 2009;102(4):226–9.
18. Barth RE, Huijgen Q, Taljaard J, Hoepelman AIM. International journal of
infectious diseases hepatitis B / C and HIV in sub-Saharan Africa : an
association between highly prevalent infectious diseases. A systematic
review and meta-analysis. Int J Infect Dis. 2010;14(12):e1024–31.
19. Ministère de la santé Burkina Faso. Annuaire statistique de sante 2016;2017.
Available from: http://cns.bf/IMG/pdf/annuaire_ms_2015_signe.pdf.
Accessed 10 Sept 2017.
20. Institut National de la Statistique et de la Démographie. Enquête
Démographique et de Santé et à Indicateurs Multiples; 2010. Available from:
http://www.dhsprogram.com/pubs/pdf/FR256/FR256.pdf. Accessed 9 Mar
2017.
21. WHO. Global health sector strategy on viral hepatitis 2016–2021;2016.
Available at http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/.
Accessed 14 Aug 2017.
22. INSD-Minsitère de l’Economie et du Développement. Recensement general
de la population et de l’habitat 2006 du Burkina Faso. 2009 [cited 19 Aug
2017]. Available from: http://www.insd.bf/documents/publications/insd/
publications/resultats_enquetes/autresenq/Resultats_definitifs_RGPH_2006.
pdf. Accessed16 July 2017.
23. United Nation. UNdata country profile Burkina Faso. [cited 6 Sep 2017].
Available from: http://data.un.org/en/iso/bf.html. Accessed 18 June 2017.
24. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred
reporting items for systematic reviews and meta-analyses: the PRISMA
statement. Ann Intern Med. 2009;151(4):264–9.
25. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.
GRADE: an emerging consensus on rating quality of evidence and strength
of recommendations. Chin J Evidence-Based Med. 2009;9(1):8–11.
26. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency
in meta-analyses. BMJ Br Med J. 2003;327(7414):557–60.
27. Andernach IE, Leiss LV, Tarnagda ZS, Tahita MC, Otegbayo JA, Forbi JC, et al.
Characterization of hepatitis delta virus in sub-Saharan Africa. J Clin
Microbiol. 2014;52(5):1629–36.
28. Bado G, Penot P, N’Diaye MD, Amiel C, Hema A, Kamboulé EB, et al. Hepatitis B
seroprevalence in HIV-infected patients consulting in a public day care unit in
Bobo Dioulasso, Burkina Faso. Médecine Mal Infect. 2013;43(5):202–7.
29. Kania D, Bekalé AM, Nagot N, Mondain A-M, Ottomani L, Meda N, et al.
Combining rapid diagnostic tests and dried blood spot assays for point-of-care
testing of human immunodeficiency virus, hepatitis B and hepatitis C infections
in Burkina Faso, West Africa. Clin Microbiol Infect. 2013;19(12):E533–41.
30. Nacro B, Dao B, Dahourou H, Hien F, Charpentier-Gautier L, Meda N, et al.
HBs antigen carrier state in pregnant women in Bobo Dioulasso (Burkina
Faso). Dakar Med. 2000;45(2):188–90.
31. Sawadogo A, Hema A, Koura M, ILBOUDO B, Kamboule B, Kabore N, et al.
Epidemiological, biological and progressive aspects of hepatitis B virus B
(HBV) infection among patients infected by human immunodeficiency virus
(HIV) in the day Hospital of Bobo-Dioulasso, Burkina Faso. J HIV AIDS. 2016;
3(2):8–13.
Lingani et al. BMC Public Health (2018) 18:551
32. Collenberg E, Ouedraogo T, Ganamé J, Fickenscher H, Kynast-Wolf G, Becher
H, et al. Seroprevalence of six different viruses among pregnant women
and blood donors in rural and urban Burkina Faso: a comparative analysis. J
Med Virol. 2006;78(5):683–92.
33. Kania D, Sangaré L, Sakandé J, Koanda A, Nébié YK, Zerbo O, et al. A new
strategy to improve the cost-effectiveness of human immunodeficiency
virus, hepatitis B virus, hepatitis C virus, and syphilis testing of blood
donations in sub-Saharan Africa: a pilot study in Burkina Faso. Transfusion.
2009;49(10):2237–40.
34. Ouédraogo AS, Ouédraoga AS, Yaméogo JT, Poda GEA, Kientega Y,
Ouédraogo Traore R. Prevalence of anti-CMV antibodies in blood donors in
Ouagadougou (Burkina Faso). Med Sante Trop. 2012;22(1):107–9.
35. Diarra B, Ouattara AK, Djigma FW, Rebeca T, Obiri-yeboah D, Traore L, et al. World
hepatitis day in Burkina Faso, 2016 : awareness, screening, identification of HBV
markers, HBV / HCV coinfection, and vaccination. Hepat Mon. 2017;17(6):4–11.
36. Ilboudo D, Karou D, Nadembega WMC, Savadogo A, Djeneba O, Pignatelli S,
et al. Prevalence of human herpes virus-8 and hepatitis B virus among HIV
seropositive pregnant women enrolled in the mother-to-child HIV
transmission prevention program at Saint Camille medical Centre in Burkina
Faso. Pak J Biol Sci PJBS. 2007;10(17):2831–7.
37. Ilboudo D, Simpore J, Ouermi D, Bisseye C, Sagna T, Odolini S, et al.
Towards the complete eradication of mother-to-child HIV/HBV coinfection
at Saint Camille medical Centre in Burkina Faso, Africa. Braz J Infect Dis.
2010;14(3):219–24.
38. Ouermi D, Simpore J, Belem AMG, Sanou DS, Karou DS, Ilboudo D, et al.
Co-infection of toxoplasma gondii with HBV in HIV-infected and uninfected
pregnant women in Burkina Faso. Pakistan J Biol Sci PJBS. 2009;12(17):1188–93.
39. Simpore J, Granato M, Santarelli R, Nsme RA, Coluzzi M, Pietra V, et al.
Prevalence of infection by HHV-8, HIV, HCV and HBV among pregnant
women in Burkina Faso. J Clin Virol. 2004;31:78–80.
40. Simpore J, Savadogo A, Ilboudo D, Nadambega MC, Esposito M, Yara J, et
al. Toxoplasma gondii, HCV, and HBV seroprevalence and co-infection
among HIV-positive and -negative pregnant women in Burkina Faso. J Med
Virol. 2006;78(6):730–3.
41. Kirakoya-Samadoulougou F, Sanou M, Samadoulougou S, Bakiono F, Kiénou
K, Koumaré A, et al. High seroprevalence of hepatitis B virus and hepatitis C
virus among human immunodeficiency virus carriers in blood donors of
Burkina Faso: a need for their screening before HARRT therapy. J Viral
Hepat. 2014;21(7):e52–3.
42. Nagalo BM, Bisseye C, Sanou M, Kienou K, Nebié YK, Kiba A, et al.
Seroprevalence and incidence of transfusion-transmitted infectious diseases
among blood donors from regional blood transfusion centres in Burkina
Faso, West Africa. Tropical Med Int Health. 2012;17(2):247–53.
43. Coffie PA, Tchounga BK, Bado G, Kabran M, Minta DK, Wandeler G, et al.
Prevalence of hepatitis B and delta according to HIV-type: a multi-country
cross-sectional survey in West Africa. BMC Infect Dis. 2017;17(1):466.
44. Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol.
2003;39 Suppl 1(10):S64–9.
45. Hou J, Liu Z, Gu F. Epidemiology and Prevention of Hepatitis B Virus
Infection. Int J Med Sci. 2005;2(1):50–7.
46. WHO. WHO issues its first hepatitis B treatment guidelines [internet]; 2015.
[cited 7 Sep 2017]. Available from: http://www.who.int/mediacentre/news/
releases/2015/hepatitis-b-guideline/en/. Accessed 12 Aug 2017.
47. Lemoine M, Shimakawa Y, Njie R, Taal M, Ndow G, Chemin I, et al.
Acceptability and feasibility of a screen-and-treat programme for hepatitis B
virus infection in the Gambia: the prevention of liver fibrosis and Cancer in
Africa (PROLIFICA) study. Lancet Glob Health. 2016;4(8):e559–67.
48. Manga NM, Diatta A, Diallo K, Kante O, Kayimba C, Diarra BB, et al. Hepatitis
B virus surface antigen carriage among blood donors in Ziguinchor,
Senegal: prevalence and associated factors. J Infect Dis Ther. 2017;5(1):10–2.
49. Tanaka J, Kumagai J, Katayama K, Komiya Y, Mizui M, Yamanaka R, et al. Sexand age-specific carriers of hepatitis B and C viruses in Japan estimated by
the prevalence in the 3,485,648 first-time blood donors during 1995-2000.
Intervirology. 2004;47(1):32–40.
50. Yugi H, Mizui M, Tanaka J, Yoshizawa H. Hepatitis B virus (HBV) screening
strategy to ensure the safety of blood for transfusion through a
combination of immunological testing and nucleic acid amplification
testing - Japanese experience. J Clin Virol. 2006;36(SUPPL. 1):56–64.
51. WHO. Guidelines for the prevention, care and treatment of persons with
chronic hepatitis B infection. 2015. Available from: http://www.who.int/hiv/
pub/hepatitis/hepatitis-b-guidelines/en/. Accessed 12 July 2017.
Page 11 of 11
52. Peto TJ, Mendy ME, Lowe Y, Webb EL, Whittle HC, Hall AJ. Efficacy and
effectiveness of infant vaccination against chronic hepatitis B in the Gambia
hepatitis intervention study (1986–90) and in the nationwide immunisation
program. BMC Infect Dis. 2014;14(1):7.
53. GARPR. Rapport d’activite sur La riposte au sida au Burkina Faso par Global
Aids Response Progress. 2016. Available from: http://www.unaids.org/sites/
default/files/country/documents/BFA_narrative_report_2016. Accessed 7
Aug 2017.
...
論文の公開元へ
